Xilio Therapeutics to be Delisted from Nasdaq
Ticker: XLO · Form: 8-K · Filed: Apr 8, 2025 · CIK: 1840233
Sentiment: bearish
Topics: delisting, nasdaq, compliance
Related Tickers: XLO
TL;DR
Nasdaq is kicking Xilio out, trading stops April 10th.
AI Summary
Xilio Therapeutics, Inc. announced on April 4, 2025, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The company has been notified that its common stock will be delisted from the Nasdaq Capital Market, with trading expected to cease on April 10, 2025.
Why It Matters
This delisting signifies a significant setback for Xilio Therapeutics, potentially impacting its ability to raise capital and its overall market valuation.
Risk Assessment
Risk Level: high — Delisting from a major exchange like Nasdaq indicates severe financial distress or non-compliance, posing a substantial risk to investors.
Key Numbers
- 001-40925 — SEC File Number (Identifies Xilio Therapeutics' filing with the SEC.)
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — The company filing the 8-K and facing delisting.
- Nasdaq Stock Market (company) — The exchange that issued the delisting notice.
- April 4, 2025 (date) — The date Xilio Therapeutics received the delisting notice.
- April 10, 2025 (date) — The expected last day of trading on Nasdaq.
FAQ
What is the primary reason for Xilio Therapeutics' delisting from the Nasdaq Capital Market?
The filing indicates that Xilio Therapeutics received a notice from the Nasdaq Stock Market regarding its failure to satisfy continued listing rule(s) or standard(s).
When is the expected last day of trading for Xilio Therapeutics' common stock on the Nasdaq Capital Market?
Trading of Xilio Therapeutics' common stock is expected to cease on the Nasdaq Capital Market on April 10, 2025.
What is the filing date of this Form 8-K?
This Form 8-K was filed as of April 8, 2025, reporting events as of April 4, 2025.
What is Xilio Therapeutics' principal executive office address?
Xilio Therapeutics' principal executive offices are located at 828 Winter Street, Suite 300, Waltham, Massachusetts 02451.
What is the Commission File Number for Xilio Therapeutics?
Xilio Therapeutics' Commission File Number is 001-40925.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 8, 2025 regarding Xilio Therapeutics, Inc. (XLO).